Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. - Dummer, R.; Hauschild, A.; Santinami, M.; Atkinson, V.; Mandalà, M.; Kirkwood, J. M.; Sileni, V. C.; Larkin, J.; Nyakas, M.; Dutriaux, C.; Haydon, A.; Robert, C.; et al. (New England Journal of Medicine, 2020)